26.06
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Revance Therapeutics Inc | RVNC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 26.06 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 26.06 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 25.50 | 32.00 | 6.50 | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 26.06 | USD |
Revance Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.73B | 66.55M | 59.10M | $ 413.00k | $ - | -3.67 | -6.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Revance Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RVNC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 26.00 | 27.09 | 24.94 | 26.06 | 475,269 | 0.06 | 0.23% |
| 1 Month | 28.04 | 30.35 | 24.94 | 27.58 | 431,027 | -1.98 | -7.06% |
| 3 Months | 24.93 | 30.45 | 23.77 | 27.55 | 470,144 | 1.13 | 4.53% |
| 6 Months | 28.48 | 34.62 | 22.89 | 27.41 | 561,060 | -2.42 | -8.5% |
| 1 Year | 23.26 | 34.62 | 11.78 | 23.63 | 578,516 | 2.80 | 12.04% |
| 3 Years | 32.95 | 34.62 | 9.88 | 21.42 | 475,733 | -6.89 | -20.91% |
| 5 Years | 18.80 | 37.45 | 9.88 | 21.97 | 385,506 | 7.26 | 38.62% |
Revance Therapeutics Description
| Revance Therapeutics Inc is a clinical-stage biotechnology company. It is focused on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company's proprietary peptide technology enables the delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. The company is pursuing clinical development for RT002 injectable in a broad spectrum of aesthetic and therapeutic indications. |
